Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jul 25, 2018
The FDA has approved AbbVie's Gonadotropin-Releasing Hormone (GnRH) antagonist Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug is branded as Orilissa, and is expected to be available in U.S. pharmacies in August. It will carry a list price of about $850 per...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper